The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

Single-country clinical trial results: Are they applicable to other populations?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The rapid acceleration of drug development has exponentially increased the therapeutic options available to patients with cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Edward S. Kim, MD, MBA, FACP, FASCO
Physician-in-Chief, Orange County; Vice Physician-in-Chief, City of Hope National Medical Center
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

EC approves Keytruda combination for a head-and-neck indication

The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1. 
Byline
Edward S. Kim, MD, MBA, FACP, FASCO
Physician-in-Chief, Orange County; Vice Physician-in-Chief, City of Hope National Medical Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account